Medically Reviewed by: Dr. Dipak Ladda, M.D.
Expertise: Consultant Pathologist
Last Updated: July 25, 2026
Medical Analysis
Comprehensive Clinical Overview and Optimization Guide for CA 15.3 and CA 27.29 Tumor Markers in Oncology
Introduction to CA 15.3 and CA 27.29 Biomarkers
CA 15-3, a glycoprotein, is a tumour marker for many types of cancer, most notably breast cancer. It is derived from MUCI [4]. CA 15-3 and associated CA 27-29 are different epitopes on the same protein antigen product of the breast cancer-associated MUC1 gene [12]. Elevated CA15-3, in conjunction with alkaline phosphatase, was found to be associated with an increased chance of early recurrence in breast cancer. Cancer antigen 15-3 (CA15-3) is a protein made by a variety of cells, particularly breast cancer cells [8]. The protein moves into the blood, where it can be measured. It is especially useful in monitoring disease progress and not for diagnosis [8].
Clinical Indications and Diagnostic Guidelines
Base level readings should be taken in breast and ovarian cancer at the time of first histopath diagnosis. The test readings may be utilized in future to monitor the disease process, response to treatment and early detection of metastasis by correlating with previous readings [9].
Advanced Laboratory Methods of Detection
ELISA: The CA 15-3 ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The microtiter wells are coated with a monoclonal [mouse] antibody directed towards a unique antigenic site of the CA15-3 molecule.
Radioimmunoassay (RIA): Here monoclonal antibody BR 15.3 to recognize a peptide sequence on the MUC-1 gene product for quantification of the CA 15-3 antigen in serum was used.
Chemiluminescence.
Sample Collection and Pre-Analytical Protocols
Collect 3.0 ml blood in plain tube (Red capped). Separate serum as early as possible and send to be.
Comprehensive Reference Range and Marker Interpretation Tables
| Marker | Reference Range | Interpretation |
| CA 15-3 | Less than 30 U/mL | Elevated in metastatic breast cancer; indicates tumor burden; rises with progression or recurrence; may elevate in benign conditions (liver disease, benign breast disorders) [8] |
| CA 27.9 | Less than 38 U/mL | Used as adjunct marker to CA 15-3; elevated levels indicate disease progression or metastasis; less sensitive for diagnosis alone [12] |
Etiological Causes of Raised CA15.3 and CA27.29 Levels
| Cause Type | Specific Causes |
| Malignant causes | Metastatic breast cancer, pancreatic, colorectal, lung, ovarian, prostate cancers [9] |
| Benign conditions | Liver disease (cirrhosis, hepatitis), Benign breast disease, Fibrocystic disease, Pregnancy, Lactation [8] |
| Other malignancies | Lung cancer, colon cancer, pancreatic cancer, prostate cancer [9] |
| Clinical significance | Elevated levels correlate with tumor burden and metastatic disease; rising levels indicate progression or recurrence [8] |
Diagnostic Workup Pathways and Protocols for Abnormal Results
Elevated levels of CA 15-3 / CA 27.29 are also associated with cancers of the ovary, lung, and prostate [9]. If these results are abnormally elevated, patient may be likely to order additional tests, including:
A repeat of the CA 15-3 / CA 27.29 test
Radiological tests, such as an ultrasound or a CT scan
Tests to check for other cancers, such as the tumour marker tests [9]
FNAC or Biopsy, if a mass is detected
Clinical Applications and Disease Monitoring Framework
| Application | Context/Details |
| Breast Cancer Monitoring | Detect recurrence, monitor therapy response [10] |
| Metastatic Disease Surveillance | Follow disease in metastatic breast cancer [11] |
| Adjunct Marker | Use CA15.3 & CA27.9 combined to increase sensitivity [12] |
| Not for Screening/Diagnosis | Limited value for initial diagnosis or screening [8] |
| Non-Breast Malignancies (Rare) | Occasionally raised in GI, lung, liver, gynecologic cancers [9] |
| Evaluation of Therapy Efficacy | Serial levels guide response assessment [10] |
Technical Limitations and Confounding Variables
CA 15-3 never remains specific for breast cancer [8]. Elevated levels are also seen with cancers of the ovary, lung, and prostate [9]. Elevated levels are also observed in noncancerous conditions such as benign breast or ovarian disease, endometriosis, pelvic inflammatory disease, and hepatitis. Elevations may also be seen in cirrhosis, sarcoidosis and lupus. Pregnancy and lactation also can raise CA 15-3 levels [8]. So, one needs to correlate values of CA15-3 with clinical details and other reports of patient [8]. One may treat the results for prognostic purpose and not for diagnostic one [8].
For Non-Medicos
Understanding Your CA 15.3 and CA 27.29 Blood Tests Made Simple
What Are CA 15.3 and CA 27.29 and Why Are They Tested?
Think of CA 15-3 and CA 27.29 as special protein flags that can show up in your bloodstream [8]. They are most commonly used by doctors to track breast cancer over time, see how well treatments are working, or check if the disease is coming back [10]. They are not generally used to find or diagnose cancer in the first place because other things can affect them too [8].
What Do Your Test Numbers Mean?
Your blood sample is measured in units per milliliter. Usually, levels below 30 U/mL for CA 15-3 and below 38 U/mL for CA 27.29 are considered normal reference ranges [8, 12]. If these numbers go up, it can mean that a tumor is growing, treatment needs adjustment, or something else is happening in your body [8].
Non-Cancer Factors That Can Raise Your Scores
Not all high scores mean cancer [8]. Things like pregnancy, breastfeeding, liver conditions like hepatitis or cirrhosis, benign breast lumps, endometriosis, and even regular inflammation can cause these protein markers to rise [8]. This is why doctors always look at your overall health history rather than just this single test [8].
What Happens Next If Your Levels Are High?
If your results come back abnormally high, your doctor will likely recommend more evaluations. This might include repeating the blood test, getting imaging scans like an ultrasound or CT scan, checking other tumor markers, or performing a biopsy if a lump is found. Your healthcare provider will use all these pieces together to understand your health completely.
References:
Copur, M. S., Wurdeman, J. M., Nelson, D., Ramaekers, R., Gauchan, D., & Crockett, D. (2018). Normalization of elevated tumor marker CA27-29 after bilateral lung transplantation in a patient with breast cancer and idiopathic pulmonary fibrosis. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 26(4), 515–518. https://doi.org/10.3727/096504017×15128550060375
Li, X., Dai, D., Chen, B., Tang, H., Xie, X., & Wei, W. (2018). Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: A meta-analysis including 12,993 patients. Disease Markers, 2018, 1–15. https://doi.org/10.1155/2018/9863092
Fejzić, H. (2015). Tumor marker CA 15-3 in breast cancer patients. Acta Medica Academica, 44(1), 39–46. https://doi.org/10.5644/ama2006-124.125
Lan, Y., Ni, W., & Tai, G. (2022). Expression of MUC1 in different tumours and its clinical significance (Review). Molecular and Clinical Oncology, 17(6), 1–10. https://doi.org/10.3892/mco.2022.2594
Chen, W., Zhang, Z., Zhang, S., Zhu, P., Ko, J. K.-S., & Yung, K. K.-L. (2021). MUC1: Structure, function, and clinic application in epithelial cancers. International Journal of Molecular Sciences, 22(12), 6567. https://doi.org/10.3390/ijms22126567
Nath, S., & Mukherjee, P. (2014). MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends in Molecular Medicine, 20(6), 332–342. https://doi.org/10.1016/j.molmed.2014.02.007
Gion, M., Mione, R., Leon, A. E., & Lusis, G. (1999). Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. Clinical Chemistry, 45(5), 630–637. https://doi.org/10.1093/clinchem/45.5.630
Duffy, M. J., Evoy, D., & McDermott, E. W. (2010). CA 15-3: Uses and limitation as a biomarker for breast cancer. Clinica Chimica Acta, 411(23–24), 1869–1874. https://doi.org/10.1016/j.cca.2010.08.032
Sturgeon, C. M., Duffy, M. J., Hofmann, B. R., Lamerz, R., Fritsche, H. A., Gaasterland, R., Hammond, M. E., & Steller, R. (2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical Chemistry, 54(12), e11–e79. https://doi.org/10.1373/clinchem.2008.105601
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C., Jr. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25(33), 5287–5312. https://doi.org/10.1200/jco.2007.14.2364
Berruti, A., Tampellini, M., Torta, M., Bitossi, R., Gorzegno, G., Faggiuolo, R., De Matteis, A., Dogliotti, L., & Angeli, A. (1994). Prognostic value in advanced breast cancer of carcinoembryonic antigen, CA 15-3, tissue polypeptide specific antigen, and mucinous like carcinoma associated antigen evaluated with multivariate analysis. Clinical Cancer Research, 11(11), 1279–1287.
Molina, R., Filella, X., Zanon, G., Pahisa, J., Muñoz, M., Velasco, M., Esquerda, A., & Ballesteros, S. (1992). Prospective evaluation of a new tumor marker, CA 27.29, in patients with breast cancer, and comparison with CA 15-3. Tumor Biology, 13(6), 332–343. https://doi.org/10.1159/000217781
Einarsson, R., Hannisdal, K., & Nustad, K. (1993). Tumour markers CA 15-3 and CA 27.29: Biochemical and clinical performance. International Journal of Biological Markers, 8(4), 211–217. https://doi.org/10.1177/172460099300800403
Safi, F., Kohler, I., Rottinger, E., & Beger, H. G. (1991). Comparison of CA 15-3, CA 19-9 and CEA in monitoring patients with breast cancer. European Journal of Surgical Oncology, 17(2), 175–182.
FAQ’s:
1. What is CA 15.3?
CA 15-3 is a glycoprotein tumor marker primarily used to monitor breast cancer.
2. How is CA 15.3 derived?
It is derived from the MUC1 gene product.
3. What are normal reference ranges?
Normal levels are below 30 U/mL for CA 15-3 and 38 U/mL for CA 27.29.
4. Can benign conditions raise levels?
Yes, liver disease, pregnancy, and benign breast disorders can elevate these markers.
5. Is it used for diagnosis?
No, these markers are primarily used for monitoring disease progress rather than initial diagnosis.
6. What sample is required?
Collect 3.0 ml of blood in a plain, red-capped tube.
7. What detection methods are used?
Methods include ELISA, radioimmunoassay (RIA), and chemiluminescence assays.
8. What causes high levels?
Malignancies like metastatic breast, lung, ovarian, and prostate cancers elevate levels.
9. What next if results elevate?
Doctors may order repeat blood tests, CT scans, ultrasounds, or a biopsy.
10. Why combine tumor markers?
Using CA 15.3 and CA 27.29 combined increases overall sensitivity for surveillance.
Related Tests
